Early results from the SCOPE I trial showed Boston Scientific Corp.’s Acurate neo transcatheter aortic valve performed worse than Edwards Lifesciences Corp.'s Sapien 3 valve.
Although the SCOPE I results are disappointing for the company, Boston Scientific remains committed to the Acurate neo platform as well as its Lotus Edge TAVR system, which was approved...